Capivasertib
| CAS No. | 1143532-39-1 |
|---|---|
| MDL No. | MFCD22628785 |
| MF | C21H25ClN6O2 |
| MW | 428.90 |
| InChI Key | JDUBGYFRJFOXQC-KRWDZBQOSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Capivasertib is an aminopiperidine with substituents at positions 1, 4, and 4: 7H-pyrrolo[2,3-d]pyrimidin-4-yl, amino, and [(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]aminocarbonyl groups, respectively. It is a pan-AKT kinase inhibitor used in combination with fulvestrant for treating adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer that has one or more PIK3CA/AKT1/PTEN alterations. It functions as an antineoplastic agent and an inhibitor of EC 2.7.11.1 (non-specific serine/threonine protein kinase). It is classified as a pyrrolopyrimidine, aminopiperidine, piperidinecarboxamide, monochlorobenzene, primary alcohol, and secondary carboxamide.
| CAS No. | 1143532-39-1 |
|---|---|
| Product Name | Capivasertib |
Biological Targets
AKT2·AKT3·AKT1
Associated Conditions
cancer·neoplasm of mature B-cells·squamous cell carcinoma·non-small cell lung carcinoma·triple-negative breast cancer·
* The information provided here is compiled from public sources and is for reference only.
